X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs AUROBINDO PHARMA - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE AUROBINDO PHARMA CADILA HEALTHCARE/
AUROBINDO PHARMA
 
P/E (TTM) x 20.1 19.3 104.4% View Chart
P/BV x 4.8 4.8 98.4% View Chart
Dividend Yield % 0.9 0.3 266.9%  

Financials

 CADILA HEALTHCARE   AUROBINDO PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
AUROBINDO PHARMA
Mar-17
CADILA HEALTHCARE/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs558895 62.3%   
Low Rs362622 58.1%   
Sales per share (Unadj.) Rs116.3254.6 45.7%  
Earnings per share (Unadj.) Rs17.939.3 45.5%  
Cash flow per share (Unadj.) Rs23.146.6 49.7%  
Dividends per share (Unadj.) Rs3.502.50 140.0%  
Dividend yield (eoy) %0.80.3 231.0%  
Book value per share (Unadj.) Rs85.4160.0 53.4%  
Shares outstanding (eoy) m1,023.74585.88 174.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.03.0 132.7%   
Avg P/E ratio x25.719.3 133.2%  
P/CF ratio (eoy) x19.916.3 122.1%  
Price / Book Value ratio x5.44.7 113.5%  
Dividend payout %19.66.4 307.8%   
Avg Mkt Cap Rs m470,664444,390 105.9%   
No. of employees `00011.814.0 84.5%   
Total wages/salary Rs m18,54517,678 104.9%   
Avg. sales/employee Rs Th10,072.710,667.8 94.4%   
Avg. wages/employee Rs Th1,569.11,264.3 124.1%   
Avg. net profit/employee Rs Th1,547.71,645.8 94.0%   
INCOME DATA
Net Sales Rs m119,049149,157 79.8%  
Other income Rs m1,1321,159 97.7%   
Total revenues Rs m120,181150,316 80.0%   
Gross profit Rs m28,47534,343 82.9%  
Depreciation Rs m5,3884,276 126.0%   
Interest Rs m911667 136.5%   
Profit before tax Rs m23,30830,558 76.3%   
Minority Interest Rs m62850 1,251.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,6447,597 74.3%   
Profit after tax Rs m18,29223,012 79.5%  
Gross profit margin %23.923.0 103.9%  
Effective tax rate %24.224.9 97.4%   
Net profit margin %15.415.4 99.6%  
BALANCE SHEET DATA
Current assets Rs m82,00592,062 89.1%   
Current liabilities Rs m60,72066,223 91.7%   
Net working cap to sales %17.917.3 103.2%  
Current ratio x1.41.4 97.1%  
Inventory Days Days73106 69.0%  
Debtors Days Days9868 145.3%  
Net fixed assets Rs m83,70362,919 133.0%   
Share capital Rs m1,024586 174.8%   
"Free" reserves Rs m86,42193,133 92.8%   
Net worth Rs m87,44593,719 93.3%   
Long term debt Rs m25,5511,814 1,408.5%   
Total assets Rs m180,653162,494 111.2%  
Interest coverage x26.646.8 56.8%   
Debt to equity ratio x0.30 1,509.6%  
Sales to assets ratio x0.70.9 71.8%   
Return on assets %10.614.6 72.9%  
Return on equity %20.924.6 85.2%  
Return on capital %22.032.7 67.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m42,68375,838 56.3%   
Fx outflow Rs m11,24230,224 37.2%   
Net fx Rs m31,44145,613 68.9%   
CASH FLOW
From Operations Rs m9,19332,786 28.0%  
From Investments Rs m-9,737-17,870 54.5%  
From Financial Activity Rs m515-19,153 -2.7%  
Net Cashflow Rs m-29-4,239 0.7%  

Share Holding

Indian Promoters % 74.8 54.1 138.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 8.0 104.4%  
FIIs % 5.9 27.7 21.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 10.2 107.8%  
Shareholders   44,069 69,601 63.3%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   ALEMBIC LTD  SHASUN PHARMA  PFIZER  FDC LTD.  ORCHID PHARMA LTD  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Up 274.4% (Quarterly Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

For the quarter ended June 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (up 274.4% YoY). Sales on the other hand came in at Rs 29 bn (up 29.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Sep 18, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - SANOFI INDIA COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS